KR100554816B1 - 비결정질 넬피나비르 메실레이트의 약학 제형 - Google Patents

비결정질 넬피나비르 메실레이트의 약학 제형 Download PDF

Info

Publication number
KR100554816B1
KR100554816B1 KR1020037014234A KR20037014234A KR100554816B1 KR 100554816 B1 KR100554816 B1 KR 100554816B1 KR 1020037014234 A KR1020037014234 A KR 1020037014234A KR 20037014234 A KR20037014234 A KR 20037014234A KR 100554816 B1 KR100554816 B1 KR 100554816B1
Authority
KR
South Korea
Prior art keywords
mesylate
nelfinavir
copolymer
nelfinavir mesylate
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037014234A
Other languages
English (en)
Korean (ko)
Other versions
KR20040007523A (ko
Inventor
인펠드마틴하워드
푸아프래딧원타니
샤나브닛하르고빈다스
창린
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20040007523A publication Critical patent/KR20040007523A/ko
Application granted granted Critical
Publication of KR100554816B1 publication Critical patent/KR100554816B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020037014234A 2001-05-03 2002-04-29 비결정질 넬피나비르 메실레이트의 약학 제형 Expired - Fee Related KR100554816B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28841001P 2001-05-03 2001-05-03
US60/288,410 2001-05-03
PCT/EP2002/004711 WO2002089835A2 (en) 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate

Publications (2)

Publication Number Publication Date
KR20040007523A KR20040007523A (ko) 2004-01-24
KR100554816B1 true KR100554816B1 (ko) 2006-02-22

Family

ID=23106974

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037014234A Expired - Fee Related KR100554816B1 (ko) 2001-05-03 2002-04-29 비결정질 넬피나비르 메실레이트의 약학 제형

Country Status (36)

Country Link
US (1) US7014866B2 (https=)
EP (1) EP1390063B1 (https=)
JP (1) JP4101661B2 (https=)
KR (1) KR100554816B1 (https=)
CN (1) CN1255185C (https=)
AR (1) AR034320A1 (https=)
AT (1) ATE282428T1 (https=)
BG (1) BG108311A (https=)
BR (1) BR0209325A (https=)
CA (1) CA2444116C (https=)
CZ (1) CZ20033211A3 (https=)
DE (1) DE60201988T2 (https=)
EA (1) EA006627B1 (https=)
EC (1) ECSP034827A (https=)
ES (1) ES2231717T3 (https=)
GE (1) GEP20053466B (https=)
GT (1) GT200200079A (https=)
HR (1) HRP20030873B1 (https=)
HU (1) HU229938B1 (https=)
IL (2) IL158306A0 (https=)
IS (1) IS7010A (https=)
JO (1) JO2401B1 (https=)
MA (1) MA27018A1 (https=)
MX (1) MXPA03009971A (https=)
MY (1) MY128509A (https=)
NO (1) NO20034689D0 (https=)
NZ (1) NZ528689A (https=)
PA (1) PA8544501A1 (https=)
PE (1) PE20021159A1 (https=)
PL (1) PL366998A1 (https=)
PT (1) PT1390063E (https=)
RS (1) RS83503A (https=)
SK (1) SK14572003A3 (https=)
TW (1) TWI234461B (https=)
UA (1) UA76463C2 (https=)
WO (1) WO2002089835A2 (https=)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (en) * 2002-01-28 2003-07-28 Pfizer Inc. Increased-dosage nelfinavir tablet and method of making same
US7495011B2 (en) 2003-07-15 2009-02-24 Arigen Pharmaceuticals, Inc. Anti-coronavirus drug
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0418330A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas de drogas de solubilidade baixa e poloxámeros
MX2007006635A (es) * 2004-12-03 2007-06-19 Merck & Co Inc Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.
DE602006011485D1 (de) * 2005-09-23 2010-02-11 Hoffmann La Roche Neue dosierformulierung
WO2007068615A2 (en) * 2005-12-14 2007-06-21 F. Hoffmann-La Roche Ag Hcv prodrug formulation
ES2350497T3 (es) * 2005-12-14 2011-01-24 F. Hoffmann-La Roche Ag Formulación de profármacos para el vhc.
PE20080422A1 (es) * 2006-08-10 2008-04-28 Cipla Ltd Composicion solida antirretroviral de administracion oral
RU2454220C2 (ru) 2006-08-16 2012-06-27 Новартис Аг Способ получения твердых дисперсий высококристаллических терапевтических соединений
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
EP2918578A1 (en) 2007-03-16 2015-09-16 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
JP2010524972A (ja) * 2007-04-19 2010-07-22 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化したモルホリニル化合物
EP2527336A1 (en) 2007-04-25 2012-11-28 Concert Pharmaceuticals Inc. Deuterated analogues of cilostazol
US8567657B2 (en) * 2007-04-30 2013-10-29 Mtj Consulting Services Inc. Coiled tubing with retainer for conduit
US9194512B2 (en) 2007-04-30 2015-11-24 Mark Andreychuk Coiled tubing with heat resistant conduit
FI3825306T3 (fi) 2007-05-01 2023-08-23 Concert Pharmaceuticals Inc Morfinaaniyhdisteitä
MX341177B (es) 2007-05-01 2016-08-10 Concert Pharmaceuticals Inc Compuestos de morfina.
US7973049B2 (en) * 2007-05-01 2011-07-05 Concert Pharmaceuticals Inc. Morphinan compounds
WO2008137461A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
AR066972A1 (es) 2007-06-12 2009-09-23 Concert Pharmaceuticals Inc Derivados azapeptidicos
WO2009051782A1 (en) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
EP2214635A1 (en) * 2007-10-19 2010-08-11 Purdue Research Foundation Solid formulations of crystalline compounds
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
KR20100121527A (ko) 2008-02-29 2010-11-17 콘서트 파마슈티컬즈, 인크. 치환된 잔틴 유도체
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
EP2334678B1 (en) 2008-09-19 2012-12-26 Concert Pharmaceuticals Inc. Morphinan compounds
WO2010062690A1 (en) 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
DK2397158T3 (en) 2008-10-30 2016-07-25 Concert Pharmaceuticals Inc COMBINATION OF MORPHINANFORBINDELSER AND antidepressants in treating pseudobulbar affect
AU2009311645C1 (en) 2008-11-04 2014-10-02 Acer Therapeutics Inc. CXCR4 receptor compounds
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
AP2909A (en) 2009-03-17 2014-05-31 Concert Pharmaceuticals Inc Pyrazinoisoquinoline Compounds
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
US8501738B2 (en) 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2536696A1 (en) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
US9155795B2 (en) 2010-02-26 2015-10-13 Anchor Therapeutics, Inc. CXCR4 receptor compounds
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8513434B2 (en) 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
EP2579859B1 (en) * 2010-06-14 2015-08-05 ratiopharm GmbH Solid ivabradine-containing composition
WO2012037060A1 (en) 2010-09-13 2012-03-22 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
CA2828251A1 (en) 2011-02-25 2012-08-30 Concert Pharmaceuticals, Inc. 2-amino-naphthyridine derivatives
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012154728A1 (en) 2011-05-10 2012-11-15 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
RS56096B1 (sr) 2011-05-18 2017-10-31 Concert Pharmaceuticals Inc Deuterisani derivati ivakaftora
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
CN104254540A (zh) 2012-01-09 2014-12-31 安科治疗公司 Apj受体化合物
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
IN2014DN08443A (https=) 2012-04-13 2015-05-08 Concert Pharmaceuticals Inc
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
AU2013274030B2 (en) 2012-06-15 2016-07-07 Sun Pharmaceutical Industries, Inc. Deuterated derivatives of ruxolitinib
US10017445B2 (en) 2012-07-12 2018-07-10 Concert Pharmaceuticals, Inc. Deuterated idebenone
CA2880083A1 (en) 2012-08-17 2014-02-20 Concert Pharmaceuticals, Inc. Deuterated baricitinib
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
EP2935251A1 (en) 2012-12-20 2015-10-28 Concert Pharmaceuticals Inc. Deuterated alk inhibitors
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US20160024084A1 (en) 2013-03-15 2016-01-28 Concert Pharmaceuticals, Inc. Deuterated palbociclib
EP2968268B1 (en) 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
EP3021861A1 (en) 2013-07-18 2016-05-25 Anchor Therapeutics, Inc. Apj receptor compounds
WO2015031741A1 (en) 2013-08-30 2015-03-05 Concert Pharmaceuticals, Inc. Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor
EP3105232B1 (en) 2014-02-10 2019-08-28 Concert Pharmaceuticals Inc. Substituted triazolobenzodiazepines
US20170216296A1 (en) 2014-04-18 2017-08-03 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
WO2015188073A1 (en) 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016094011A1 (en) * 2014-12-11 2016-06-16 Merck Sharp & Dohme Corp. Crystal forms of a ccr5 antagonist
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
EP3265440A1 (en) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Deuterated emricasan
EP3277647A1 (en) 2015-03-31 2018-02-07 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
WO2017020002A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
KR102828163B1 (ko) 2015-09-21 2025-07-02 버텍스 파마슈티칼스 (유럽) 리미티드 중수소화된 cftr 강화제의 투여
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
CN108602806B (zh) 2015-12-09 2022-07-12 研究三角协会 改进的爱帕琳肽受体(apj)激动剂及其用途
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP4122919A1 (en) 2016-07-04 2023-01-25 Avanir Pharmaceuticals, Inc. Methods for the synthesis of deuterated dextromethorphan
CN109789103A (zh) 2016-08-01 2019-05-21 布里格姆妇女医院 用于递送蛋白质和肽的颗粒
CA3036382A1 (en) 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
EP3589659B1 (en) 2017-02-28 2025-04-09 Mayo Foundation for Medical Education and Research Combinations for use in the treatment of cancer
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
BR112019024177A2 (pt) 2017-05-19 2020-06-02 Superb Wisdom Limited Derivados de resiquimode
CN111491629A (zh) 2017-11-22 2020-08-04 康塞特医药品公司 D-丝氨酸的氘化类似物及其用途
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
WO2020210707A1 (en) 2019-04-10 2020-10-15 Mayo Foundation For Medical Education And Research Methods and materials for gender-dependent treatment of cardiovascular dysfunction
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CA3184471A1 (en) 2020-05-27 2021-12-02 The Penn State Research Foundation Antibacterial compounds
JP2023553253A (ja) 2020-10-28 2023-12-21 サン ファーマシューティカル インダストリーズ，インコーポレイテッド 重水素化ｊａｋ阻害剤による脱毛障害の治療のためのレジメン
JP2024507574A (ja) 2021-02-25 2024-02-20 リサーチ トライアングル インスティテュート アペリン受容体アゴニストとしてのヘテロアリール誘導体
AU2022328272A1 (en) 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
EP4384173A1 (en) 2021-08-12 2024-06-19 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
US20250275977A1 (en) 2022-05-04 2025-09-04 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2290624C (en) * 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
WO1999013864A2 (en) * 1997-09-19 1999-03-25 Shire Laboratories, Inc. Solid solution beadlet
DK1227797T3 (da) * 1999-11-12 2005-05-30 Abbott Lab Farmaceutiske faststofdispersionsformuleringer
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation

Also Published As

Publication number Publication date
EP1390063A2 (en) 2004-02-25
IL158306A0 (en) 2004-05-12
HK1070285A1 (en) 2005-06-17
MY128509A (en) 2007-02-28
US20030021840A1 (en) 2003-01-30
CA2444116A1 (en) 2002-11-14
ECSP034827A (es) 2003-12-24
GT200200079A (es) 2002-12-05
PE20021159A1 (es) 2002-12-20
JP4101661B2 (ja) 2008-06-18
HUP0401238A3 (en) 2012-09-28
PA8544501A1 (es) 2002-11-18
ES2231717T3 (es) 2005-05-16
MXPA03009971A (es) 2004-02-12
BR0209325A (pt) 2004-07-20
TWI234461B (en) 2005-06-21
HUP0401238A2 (hu) 2004-12-28
UA76463C2 (en) 2006-08-15
NZ528689A (en) 2005-03-24
IL158306A (en) 2008-11-03
DE60201988T2 (de) 2005-12-15
US7014866B2 (en) 2006-03-21
NO20034689L (no) 2003-10-20
JO2401B1 (en) 2007-06-17
RS83503A (sr) 2006-10-27
NO20034689D0 (no) 2003-10-20
CN1547484A (zh) 2004-11-17
CZ20033211A3 (cs) 2004-09-15
EA200301166A1 (ru) 2004-04-29
WO2002089835A2 (en) 2002-11-14
DE60201988D1 (de) 2004-12-23
EP1390063B1 (en) 2004-11-17
WO2002089835A3 (en) 2003-05-01
ATE282428T1 (de) 2004-12-15
AR034320A1 (es) 2004-02-18
GEP20053466B (en) 2005-02-25
HRP20030873B1 (en) 2006-04-30
CN1255185C (zh) 2006-05-10
SK14572003A3 (sk) 2004-12-01
HU229938B1 (en) 2015-01-28
BG108311A (bg) 2004-12-30
CA2444116C (en) 2009-01-20
MA27018A1 (fr) 2004-12-20
JP2004527569A (ja) 2004-09-09
EA006627B1 (ru) 2006-02-24
IS7010A (is) 2003-10-30
PT1390063E (pt) 2005-03-31
PL366998A1 (en) 2005-02-07
KR20040007523A (ko) 2004-01-24
HRP20030873A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
KR100554816B1 (ko) 비결정질 넬피나비르 메실레이트의 약학 제형
JP3162626B2 (ja) イルベサルタン含有医薬組成物
US7976869B2 (en) Fenofibrate tablets
US20160158203A1 (en) Methods of treatment with bioavailable compositions of metaxalone comprising nonvolatile liquids
US20090209587A1 (en) Repaglinide formulations
JP2010280707A (ja) メシル酸サキナビル経口投与剤型
JP5318400B2 (ja) レボフロキサシン含有錠剤
AU2002319154B2 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
JP3470096B2 (ja) ニルバジピン含有易溶性固形製剤およびその製造法
RU2847102C1 (ru) Диспергируемые таблетированные композиции, содержащие долутегравир
AU2002319154A1 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
JP2023522362A (ja) 安全性と安定性が改善されたピルフェニドンを含む腸溶性製剤およびその製造方法
US20170273923A1 (en) Method of administering divalproex
HK1070285B (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
HK1184690A (en) Bioavailable solid dosage forms of metaxalone
HK1002384B (en) Pharmaceutical compositions containing irbesartan
JPWO1997040828A1 (ja) Ｓ１４５２の速放性錠剤

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20130130

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20140129

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20150129

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180217

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180217

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000